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1 Drug description 
Generic/Brand name:  
Panitumumab/Vectibix ® 
Developer/Company:  
Amgen Europe B.V. 
Description:  
Panitumumab is a fully human monoclonal antibody targeting the epider-
mal growth factor receptor (EGFR) which can be found on the surface of 
certain cancer cells such as colorectal cancer (CRC) cells. Consequently, the 
EGFR expressing tumour cells no longer receive messages needed for 
growth transmitted via EGFR and therefore progression and spreading of 
the tumour cells is stopped [1]. Further, panitumumab shows no clinical ef-
ficacy in tumour cells expressing mutated KRAS [2], because the growth of 
tumour cells containing mutated KRAS is no longer controlled by EGF re-
ceptors [1]. 
KRAS gene analysis in metastatic disease is recommended as it is very im-
portant regarding responsiveness to treatment with EGFR targeted therapies 
such as panitumumab and cetuximab [3]. Cetuximab, the second EGFR tar-
geting antibody is – in contrast to panitumumab, a chimeric monoclonal an-
tibody approved for the treatment of colorectal carcinoma and for the treat-
ment of squamous cell cancers of the head and neck [2, 4]. 
The recommended dose of panitumumab is 6mg/kg body weight given once 
every other week as an intravenous infusion (iv) over 60 minutes when the 
administered infusion is ≤1000ml. Infusion time is extended to 90 minutes 
when the infusion is >1000 ml [1]. 
2 Indication 
Within this assessment, the indication of interest for panitumumab is the 
1st- and 2nd-line treatment of patients with metastatic colorectal cancer 
(mCRC) in combination with chemotherapy, either FOLFOX or FOLFIRI. 
The FOLFOX regimen consists of fluorouracil, leucovorin and oxaliplatin 
and the FOLFIRI regimen combines fluorouracil, leucovorin and irinotecan 
[5]. 
3 Current regulatory status 
Since December 2007 Vectibix ® is approved in Europe for the treatment of 
patients with EGFR expressing metastatic colorectal cancer with non-
mutated, so called wild-type, KRAS after failure of previous chemotherapy 
regimens based on one of the following chemotherapeutic agents: fluoro-
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pyrimidine, oxaliplatin or irinotecan. Panitumumab is approved as 3rd-line 
mono-therapy [1]. 
Conditional marketing authorization was granted to Vectibix ® by Euro-
pean Medicines Agency (EMA). They requested further information particu-
larly regarding safety and effectiveness in patients whose tumour contain 
non-mutated KRAS and their quality of life. This request includes studies 
that investigate the use of panitumumab in different combinations with 
other drugs at different treatment lines and the effectiveness of panitumu-
mab as mono-therapy [1]. 
FDA approved Vectibix ® for the same indication as EMA in 2006. As EMA, 
FDA granted accelerated marketing authorization, requesting mature data 
on clinical benefit and patient relevant outcomes of panitumumab, not only 
surrogate endpoints [6]. 
4 Burden of disease 
Colorectal cancer is worldwide the third most common type of cancer [7]. In 
2007, there were 4462 (2478 men, 1984 women) new cases of colorectal can-
cer diagnosed in Austria. These are about 13% of all new cancer cases in 
Austria in 2007 [8]. In the same year 2210 (1178 men, 1032 women) CRC pa-
tients died in Austria [9]. 
At time of diagnosis between 15-25% of colorectal cancer patients suffer 
from advanced disease and approximately 50% of all CRC patients will de-
velop metastatic disease [10]. Applying these estimates to the Austrian con-
text, approximately 2231 patients are eligible for 1st-line metastatic CRC 
treatment (mCRC). 
The 5-year survival rate for colorectal cancer patients suffering from metas-
tatic disease at time of diagnosis is between 44-83% [3]. The most widely 
applied staging system in colorectal cancer patients is the TNM staging sys-
tem [3, 11-12]. Besides the prognostic value of the staging system it is used 
as the basis for discussion on the choice of therapy[3]. 
Study results show, that KRAS status is an essential prognostic factor in re-
spect to responsiveness of tumours to EGFR targeting anticancer medicine. 
Approximately 40% of all patients suffering from metastatic colorectal can-
cer have KRAS-mutated tumour cells. Consequently, the treatment with 
EGFR-targeting antibodies is not considered to be effective [11-12]. 
Within the last 10 years, different targeted therapies such as monoclonal an-
tibodies (moAbs) were developed and approved for the treatment of CRC. 
These moAbs target different receptors at the surface of the tumour cell and 
inhibit the growth and spreading of the tumour. The currently most widely 
used receptors for the choice of therapy are vascular endothelial growth fac-
tor (VEGF) and epidermal growth factor receptor (EGFR) [13]. Bevacizu-
mab, a moAb targeting the VEGF demonstrated a clinical relevant im-
provement of overall survival from 15.6 to 20.3 months when added to iri-
notecan and 5-fluorouracil (5-FU) compared to these regimens alone in the 
1st-line setting [10]. The two other relatively new agents, cetuximab and 
panitumumab are targeting the EGFR of tumour cells. Cetuximab is ap-
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proved for 1st-, 2nd- and 3rd-line therapy in KRAS wild-type (WT) metastatic 
colorectal cancer [4, 14]. 
The rationale behind the PACCE study, the basis of this assessment, is to 
investigate, if the addition of panitumumab to bevacizumab and chemother-
apy is more effective than bevacizumab and chemotherapy alone, as these 
two monoclonal antibodies bind to different growth factors. 
5 Current treatment 
Patients diagnosed with metastatic colorectal cancer should first be evalu-
ated if they are eligible for surgery. Patients who cannot undergo resection 
are considered to be candidates for radiofrequency ablation (RFA) which is, 
according to study results considered to be inferior to surgery in terms of lo-
cal recurrence and 5-year overall survival [12]. 
Those patients who suffer from unresectable disease should receive chemo-
therapy for advanced or metastatic disease [12]. Currently there are five dif-
ferent classes of drugs available which show significant anti-tumour activity 
when used as single agents or in different combinations in mCRC. These 
classes of drugs are: 
 Fluoropyrimidines (5-fluorouracil, also widely known as 5-FU) 
 Irinotecan 
 Platinum agent Oxaliplatin 
 Monoclonal antibody targeting EGFR (cetuximab and panitumu-
mab) 
 Monoclonal antibody targeting VEGF (bevacizumab)[15] 
The choice of therapy is based on consideration of the goal of the therapy, 
the type and timing of the prior therapy that has been administered and the 
differing toxicity profiles of the constituent drugs [12]. 
Until the beginning of the 20th century the combination of 5-fluorouracil and 
leucovorin (5-FU/LV) was the basis of therapy for mCRC. In the following 
years, studies were conducted either adding irinotecan or oxaliplatin to 5-
FU/LV (FOLFIRI or FOLFOX, respectively1) [16]. Due to increases in dis-
ease free survival and overall survival these two regimens are currently con-
sidered to be standard of care in combination with bevacizumab and 
cetuximab in the 1st-line treatment of metastatic colorectal cancer. Both, 
FOLFIRI and FOLFOX are considered to be adequate choices for 1st-line 
therapy [15] and study results also suggest that they are effective when used 
interchangeable for 1st- and 2nd-line therapy [16-17]. 
The development of therapy for mCRC is described elsewhere in more detail 
[11-13]. 
                                                             
1 FOLFIRI – combination therapy consisting of 5-fluorouracil, leucovorin and iri-
notecan; FOLFOX – combination therapy consisting of 5-fluourouracil, leucovorin 
and oxaliplatin 
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6 Evidence 
Two phase III studies (PRIME trial and PACCE trial) assessing the efficacy 
of panitumumab in combination with standard of care versus standard of 
care (PRIME trial [18-20]) and bevacizumab in combination with chemo-
therapy with or without panitumumab (PACCE trial [5, 17]) for the 1st-line 
treatment of metastatic colorectal cancer could be identified. The PRIME 
trial is an ongoing trial investigating the treatment effect of panitumumab 
in combination with FOLFOX in 1183 mCRC patients. Interim results on 
safety and efficacy presented at the Gastrointestinal Cancers Symposium 
2010 and at the meeting of the European Society for Medical Oncology 
(ESMO) in 2009 are listed in table 6.1-1. 
The intention of the PACCE trial was to determine whether the addition of 
panitumumab to standard of care FOLFOX and FOLFIRI regimens, both in 
combination with bevacizumab, will help patients being treated for previ-
ously untreated mCRC [5, 17]. Due to decrease in PFS and unacceptable 
toxicity in the investigational arm, treatment with panitumumab was halted 
in March 2007. The descriptive analysis regarding safety and efficacy pre-
sented in the table below is based on data available as of May 2007. 
All in all, these 2 trials include 2236 patients suffering from previously un-
treated metastatic colorectal cancer. 
Further, one phase II multicenter trial [21] of panitumumab for first-line 
treatment of metastatic colorectal cancer consisting of two parts was identi-
fied. The aim of part1 (n=19) was to assess PFS and of part2 to determine 
the incidence of grade 3/4 diarrhoea. 
6.1 Efficacy and safety - Phase III studies 
Table 6.1-1: Phase III trials - efficacy and safety of panitumumab in mCRC 
Reference  Hecht et al. (2009) [5] (PACCE) Siena et al. (2010 ) [18, 20] (PRIME); Ab-
stract only 
Sponsor Supported by Amgen Inc. Amgen 
Country USA 116 study locations worldwide [22] 
Design Randomized, open-label multicenter (200) phase III 
study 
Randomized, multicenter phase III study 
Participants character-
istics 
N=1053 (randomized pts), overall median age 60.5 
years; 
I: 528 (Ox-CT: 413; Iri-CT: 115) 
C: 525 (Ox-CT: 410; Iri-CT: 115) 
N=1183; demographics were balanced 
I: 593 patients 
C: 590 patients 
1096/1183 pts had KRAS results: 656 WT; 440 
mutant (MT) 
Treatments I(ntervention): 2 cohorts both with bevacizumab 
every 2 weeks (Q2W); doses were chosen by the in-
vestigator 
- Ox-CT: fluorouracil, leucovorin, oxaliplatin 
- Iri-CT: fluorouracil, leucovorin, irinotecan 
Pts received concomitant panitumumab of 6 mg/kg 
Q2W 
C(ontrol): 
The same treatment regimen as intervention group 
but without panitumumab 
Intervention: 6.0 mg/kg panitumumab Q2W 
+ FOLFOX4 Q2W 
Control: FOLFOX4 Q2W alone 
2 phase III trials 
 
PRIME ongoing – 
panitumumab + 
chemotherapy 
PACCE – panitumumab 
+ bevacizumab + 
chemotherapy 
trial halted by the 
sponsor 
one phase II trial 
consisting of 2 parts 
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In-/exclusion criteria Inclusion: pathologic diagnosis of mCRC with meas-
urable disease per RECIST2 
ECOG PS3 0 or 1, adequate hematologic, hepatic and 
renal functions 
 
Exclusion: prior chemotherapy or biologic therapy 
for metastatic disease; adjuvant chemotherapy 
within 6 months of undergoing random assignment, 
major surgery within 28 days of random assignment, 
pre-existing bleeding diathesis or coagulopathy 
Inclusion: histologically/cytologically-
confirmed adenocarcinoma of the colon or 
rectum with metastatic disease, no prior 
chemotherapy or systemic therapy for mCRC, 
no prior oxaliplatin, ECOG PS 0-2 
No EGFR staining required for inclusion. 
Follow-up Study drug discontinuation in March 2007, cut-off 
date May 2007. 
Trial ongoing – estimated completion time 
March 2011[22] 
Outcomes Primary: Ox-CT arm: progression free survival (PFS); 
Iri-CT arm: safety 
Secondary (both cohorts): objective response rate 
(RR), overall survival (OS) and safety 
Primary: PFS 
Secondary: OS, objective response rate, time 
to progression, duration of response and 
safety 
Key results  
 
Median PFS time I vs. C in May 2007: 
- Ox-CT: 10 months (mths) (95% CI, 8.9 to 11) vs. 11.4 
mths (95% CI, 10.5 to 11.9) 
- Iri-CT: 10.1 vs. 11.7 mths (HR 1.19; 95% CI, 079 to 
1.79) 
 
Secondary endpoints I vs. C in May 2007: 
RR: 
- Ox-CT: 46% vs. 48% (OR 0.92; 95% CI, 0.7 to 1.22)
- Iri-CT: 43% vs. 40% (OR 1.11; 95% CI, 0.65 to 1.90 
OS: 
- Ox-CT: 19.4 mths (95% CI, 18.4 to 20.8) vs. 24.5 
mths (95% CI, 20.4 to 24.5), (HR 1.43; 95% CI, 1.11 to 
1.83) 
- Iri-CT: 20.7 vs. 20.5 mths (HR 1.42; 95% CI, 0.77 to 
2.62) 
Pts with wild type KRAS tumours : median 
PFS – I: 9.6 mths vs. C: 8.0 mths (HR 0.8, 
95% CI, 0.66-0.97; p=0.02); RR – I: 55% vs. 
C: 48% 
Pts with mutant KRAS tumours: median PFS 
– I: 7.3 mths vs. C: 8.8 mths (HR 1.29, 95% CI, 
1.04-1.62; p=0.02)  
 
No OS data presented in the available ASCO 
abstract 
Adverse effects Safety analysis included 804pts Ox-CT-cohort and 
224 pts Iri-CT cohort: 
Worst grade 3 or higher AEs I vs. C: 
- Ox-CT: 367 (90%) vs. 305 (77%) 
- Iri-CT: 100 (90%) vs. 71 (63%) 
Adverse events included garde 3/4  skin toxicity, diar-
rhoea, infections, pulmonary embolism 
7 of 293 deaths were attributed  by the investigator 
to be panitumumab related (pulmonary embolism, 
cardiac arrest, cancer progression, arrhythmia, intes-
tinal perforation, sepsis) 
AE s were comparable across arms with ex-
ception of known toxicities associated with 
anti-EGFR therapy. 
Grade 3/4 infusion reactions related to pani-
tumumab treatment were observed in less 
than 1% of patients. 
Commentary Study was halted in 2007 due to decrease of PFS and 
increase of toxicity when panitumumab was added 
to chemotherapy 
 
KRAS analysis showed adverse outcomes for the 
panitumumab arm in both wild-type and mutant 
groups 
 
Administration of chemotherapy and dual 
EGFR/VEGF inhibition (panitumumab plus bevaci-
zumab) not recommended for treatment of mCRC in 
clinical practice 
PFS superior in wild type KRAS tumours than 
in mutant KRAS tumours 
 
No data available on OS 
 
No details available on adverse events (no 
full publication) 
 
                                                             
2 RECIST – Response Evaluation Criteria in Solid Tumours 
3 ECOG PS – Eastern Cooperative Oncology Group performance status 
HR – hazard ratio, OR – odds ratio, RR – response rate, pts – patients, Q2W – every 
two weeks, WT – wild type, MT – mutated; AEs – adverse events, FOLFOX4 
– combination therapy of 5-fluorouracil, leucovorin and oxaliplatin 
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Due to decrease in PFS and increase of toxicity observed in the panitumu-
mab arm, panitumumab was discontinued on both, bevacizumab + 
FOLFIRI and bevacizumab + FOLFOX cohorts in March 2007 in the 
PACCE trial. At time of data analysis in May 2007, 94% of the Ox-CT co-
hort and 87% in the Iri-CT cohort had ended study treatment. Most of these 
patients discontinued the study treatment due to AEs, treatment refusal and 
requirement of alternative therapy. KRAS mutation status was analysed in 
82% of patient tumour samples. Results show that PFS favoured the control 
arm in both chemotherapy cohorts, regardless of KRAS status. Differentiat-
ing between FOLFIRI and FOLFOX cohorts, response rates (RR) were 
similar between intervention and control arm in both KRAS groups in the 
FOLFOX cohort. For the irinotecan-based cohort RR was numerically 
higher in the wild-type group for the intervention group and for the mutant 
group in the control arm [5]. 
The PRIME trial was designed to demonstrate the importance of KRAS 
status as a predictive biomarker for the selection of 1st-line therapy for me-
tastatic colorectal cancer with panitumumab (anti-EGFR monoclonal anti-
body) in combination with oxaliplatin-based chemotherapy (FOLFOX). Re-
sults of the PRIME trial confirm the importance of determining the KRAS 
status as a predictive biomarker for the choice of therapy [18]. Besides the 
interim safety analysis presented 2010 at the annual meeting of the Ameri-
can Society of Clinical Oncology (ASCO) [18], another ASCO abstract from 
2008 is available presenting the pooled safety data on the first 601 patients 
[19]. The most common grade 3/4 AEs observed were skin and subcutaneous 
tissue of system organ class (11%), diarrhoea (10%), nausea (3%), neutro-
penia (25%), fatigue (4%), hypomagnesaemia (2%) and dehydration [19]. 
Whereas, the PACCE trial was started in June 2005 and halted in March 
2007 due to decrease in PFS and unacceptable toxicities, the PRIME trial 
started in July 2006 and is still ongoing. OS results and safety results are 
available from the abstracts of presentations at ESMO meeting 2009 [20] 
and the 2010 ASCO Gastrointestinal Cancer Symposium [18]. These results 
show that the addition of panitumumab to chemotherapy in 1st-line treat-
ment is superior with respect to PFS in wild-type KRAS tumours compared 
to chemotherapy alone [18, 20]. 
decrease in PFS 
increase toxicities 
PFS favoured control 
arm regardless of KRAS 
status 
KRAS as predictive 
biomarker for choice of 
therapy 
importance of KRAS 
status confirmed 
panitumumab improves 
PFS in combination with 
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6.2 Efficacy and safety - further studies 
Berlin et al. [21] conducted a phase II multicenter, open-label study consist-
ing of two parts to assess the efficacy of panitumumab in combination with 
irinotecan-based chemotherapy (irinotecan, leucovorin and 5-fluorouracil) 
for untreated mCRC. The two parts of the study differed regarding the mode 
of administration of 5-fluorouracil which was given either as bolus intrave-
nous (part1; n=19) or as an intravenous (i.v.) infusion (FOLFIRI, part2; 
n=24). The dose of panitumumab was 2.5 mg/kg given intravenously once 
weekly. The primary objective of part1 was to assess progression free sur-
vival (PFS) and as patients experienced unacceptable toxicity in part1 of the 
study, the protocol was amended to replace part1 by part2 and also the pri-
mary endpoint was changed to assess the incidence of grade 3/4 diarrhoea. 
11 (58%) and 6 (25%) patients suffered from grade 3 or 4 diarrhoea in part1 
and 2, respectively. All in all, 4 patients discontinued treatment due to grade 
3/4 diarrhoea, 3 in part1 and one in part2. Other treatment related grade 3/4 
adverse events observed in both parts were pain, dehydration, hypokalaemia 
and fatigue and grade 4 hypomagnesaemia which was considered to be 
treatment related. Skin-related toxicities – common AEs of EGFR-targeting 
agents – related to treatment occurred in all patients included in the trial. 
16% of patients in part1 and 13% in part2 had grade 3 skin-related reac-
tions. Rash was the most common event of skin-related toxicities. Overall, 6 
(32%) patients and 11 (46%) patients in part1 and 2 discontinued treatment 
due to adverse events – 5 and 8 patients suffered from AEs considered to be 
panitumumab related, respectively. Whereas in part1 2 patients died during 
the panitumumab treatment, none of the deaths was study drug related. No 
patient died in part2. The median PFS time was 5.6 months (95% CI, 4.4-8.3 
months) in part1 and 10.9 months (95% CI, 7.7-22.5) in part2 and the me-
dian overall survival (CI 95%) was 17 months (13.7 to not estimable) and 
22.5 months (14.4 to not estimable), respectively. 
7 Estimated costs 
It is recommended that panitumumab is administered as an intravenous in-
fusion at 6mg/kg over 60 (≤1000 ml) or 90 (>1000 ml) minutes every 14 days 
[23]. In Austria, the price for one vial of 5ml containing 20mg/ml panitu-
mumab is €425.- (manufacturer’s price [24]; pharmacy retail price: €707.20 
[25]). Assuming an average weight of 70kg of patients, 5 vials are needed for 
one treatment cycle of two weeks. Therefore the monthly treatment costs for 
panitumumab mono-therapy would be €4,250.- (€7,072.-). 
If the immunotherapy with panitumumab would be used as 1st-line therapy 
in combination with standard of care (see chapter 5) these costs would be 
additional to the treatment costs of standard of care. Further, as study re-
sults show that EGFR-targeting agents are not effective in KRAS-mutated 
tumours, genotyping is strongly recommended prior the therapy, ideally at 
time of diagnosis of mCRC [11-12]. 
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8 Ongoing research 
At the trial registry website ClinicalTrials.gov of the U.S. National Institutes 
of Health are several phase III trials registered, investigating the efficacy 
and safety in different treatment options (June 2010). Most of the studies in-
vestigate the anti-cancer ability of panitumumab in the second-line setting. 
Two studies, briefly described below, are conducted in the first-line setting: 
 FOxTROT trial (NCT00647530) – fluoropyrimidine, oxaliplatin 
and targeted receptor pre-operative therapy: a controlled trial in 
high-risk operable colon cancer. The aim of this trial is to investi-
gate whether the addition of panitumumab to fluorouracil and ox-
aliplatin is superior in terms of efficiency and safety to fluorouracil 
and oxaliplatin alone in the treatment of patients with high-risk co-
lon cancer that can be removed by surgery. The estimated comple-
tion date of this trial is January 2012. 
 PRIME trial (NCT00364013I) – the purpose of this study is again 
to investigate the efficacy and safety of adding panitumumab to 
standard of care in the 1st-line treatment of mCRC. In chapter 6 of 
this assessment interim safety and efficacy results presented at 
ASCO meetings in 2008 and 2010 are described [18-19]. As men-
tioned above, the PRIME trial is estimated to be completed in 
March 2011. 
9 Commentary 
Vectibix ® was approved by FDA and EMA in 2006 and 2007, respectively 
as mono-therapy for the treatment of mCRC after irinotecan- or oxaliplatin-
based chemotherapy has failed [1, 23]. Both, EMA and FDA granted accel-
erated/conditional approval based on one open-label, randomized multina-
tional study (n=463 patients) not showing a survival difference between the 
intervention and the control arms, but superior PFS in the panitumumab 
arm [14, 26-27]. If drugs are granted accelerated or conditional approval 
based on surrogate endpoint(s) that are likely to predict effects on OS, the 
marketing authorization holder is obliged to conduct further studies to ver-
ify the clinical benefit of the medicine [26]. These new results of the trials 
are then reviewed every year by the regulatory authority [14]. 
The PACCE trial was conducted to find out whether panitumumab is effec-
tive in the 1st-line therapy of mCRC. One very important point to note is 
that this trial investigated the antitumor activity of two monoclonal antibod-
ies, each targeting a different receptor on the surface of tumour cells in 
combination with chemotherapy. Recent studies demonstrated the superior-
ity of adding bevacizumab to either FOLFOX or FOLFIRI compared to one 
of these regimens alone. The rationale behind the PACCE trial was, to im-
prove efficacy by blocking two growth factors on the surface of cancer cells – 
VEGF with bevacizumab and EGFR with panitumumab. 
several phase III trials 
registered at 
www.clinicaltrial.gov 
pre-operative therapy 
combination 
panitumumab with 
standard of care in 1st-
line therapy of mCRC 
approved as mono-
therapy in 2nd-line 
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Within the FDA review, Giusti et al. (2009) expressed 3 major concerns on 
the PACCE trial. First of all, they criticized that the assessment, whether the 
risks of panitumumab treatment could outweigh its benefit was conducted at 
the time of interim analysis. The time when to conduct the interim analysis 
was event driven and all patients had already been accrued. Originally, the 
purpose of the data safety monitoring board (DSMB) was to stop accrual 
when the risks of panitumumab are superior to its benefit. Further, the FDA 
advised the sponsor in advance about its concerns regarding the study de-
sign and the lack of phase II trial data with the combination of panitumu-
mab and bevacizumab plus chemotherapy. And finally Giusti et al. ex-
pressed concern about the consistency of the results of retrospective KRAS 
analysis and the hypothesis that response in patients with wild-type KRAS is 
superior to that in patients with mutated KRAS tumours [26]. 
Several retrospective analyses and studies show that the monoclonal anti-
bodies panitumumab and cetuximab are not suitable for therapy in patients 
with KRAS mutated cancer cells [28]. It is estimated that about 40% of colo-
rectal cancer have mutated KRAS. Therefore, guidelines suggest KRAS 
status testing at time of diagnosis of mCRC. The early establishment of the 
KRAS status does not necessarily influence the therapy selection for 1st-line 
setting, but enables oncologists and patients to develop a targeted, continu-
ous treatment strategy – especially in deciding whether to use EGFR-
targeting argents or not [11-12]. 
At the beginning of June 2010 EMA released a summary of the European 
Public Assessment Report on Vectibix ® [14] stating among other things 
that they are still awaiting results of studies investigating the clinical benefit 
of panitumumab in combination with other medicines or as a single agent in 
different treatment lines of patients with colorectal cancer with and without 
KRAS mutation. Further, the quality of life of patients treated with panitu-
mumab needs to be determined [14]. 
Based on the results of the PACCE trial and also of the CAIRO-2 trial, when 
cetuximab was added to capecitabine, oxaliplatin and bevacizumab for the 
1st-line treatment of mCRC [29-30] guidelines strongly advise against the 
concurrent use of bevacizumab with either cetuximab or panitumumab [11-
12]. In both studies the progression free survival in the investigational study 
arm was inferior to the control arm [5, 29]. 
To date, there are no data available on the quality of life (QoL) of patients 
treated with panitumumab [14] and currently trial results have only demon-
strated benefit of panitumumab in treatment of chemotherapy refractory 
mCRC [13]. 
Though, panitumumab is approved in the US and in Europe, there still re-
main questions to be answered in terms of patient relevant benefit for 
mCRC patients. Based on trial results the concomitant use of panitumumab 
and bevacizumab is not recommended. Further, data demonstrating the ef-
fectiveness regarding OS and QoL of mCRC patients treated with panitu-
mumab in the 1st-line setting should be provided before the widespread 
clinical use. 
 
3 major concerns: 
first benefit-risk analysis 
was event driven 
lack of phase II trials 
 
relevance of KRAS 
status for mCRC therapy 
moAbs targeting EGFR 
not effective in pts with 
KRAS mutated tumour 
KRAS testing at time of 
diagnosis 
clinical benefit still 
needs to be proven 
guidelines advise not to 
use bevacizumab in 
combination with EGFR-
targeting moAbs 
to date no quality of life 
data available 
patient relevant benefit 
still remains to be 
answered more precisely 
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